2025 European Guidelines Clarify the Role of Prescription EPA

On 29 August 2025, the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) published a focused update to their dyslipidaemia guidelines. Among its changes, the document sharpens the distinction between a specific prescription omega-3 therapy and the broader category of omega-3 products. ESC

A recommendation for a defined patient group

The update states that high-dose icosapent ethyl, 2 g twice daily, should be considered alongside a statin for patients at high or very high cardiovascular risk with fasting triglycerides of 1.52–5.63 mmol/L (135–499 mg/dL). This carries a Class IIa, Level B recommendation. It is a treatment option for clinical assessment, not a recommendation that everyone take omega-3 supplements. Official recommendation

Why the formulation matters

Icosapent ethyl was studied in REDUCE-IT, a randomized trial involving statin-treated patients with established cardiovascular disease or diabetes plus additional risk factors. The trial found fewer major cardiovascular events with the tested treatment than with placebo. It also found more hospitalizations for atrial fibrillation or flutter, underlining the need to consider safety alongside potential benefit. REDUCE-IT

A different trial, STRENGTH, tested a high-dose formulation containing both EPA and DHA. It did not demonstrate a significant reduction in its main cardiovascular outcome compared with corn oil. The studies used different preparations and designs, so they should not be treated as a direct head-to-head comparison. STRENGTH

For readers following pharmaceutical and nutritional science, the distinction is important. An ingredient category alone does not establish equivalent clinical performance across products. Findings must be interpreted in relation to the formulation, dose, study population and outcome measured.

The guideline update does not establish cardiovascular benefits for ordinary fish-oil supplements or other untested products. Decisions about prescription treatment should be made with a healthcare professional, taking individual risk and local prescribing requirements into account.